765 related articles for article (PubMed ID: 32327907)
1. Gastrointestinal cancer stem cells as targets for innovative immunotherapy.
Chivu-Economescu M; Necula LG; Matei L; Dragu DL; Neagu AI; Alexiu I; Bleotu C; Diaconu CC
World J Gastroenterol; 2020 Apr; 26(14):1580-1593. PubMed ID: 32327907
[TBL] [Abstract][Full Text] [Related]
2. Challenges and opportunities for cancer stem cell-targeted immunotherapies include immune checkpoint inhibitor, cancer stem cell-dendritic cell vaccine, chimeric antigen receptor immune cells, and modified exosomes.
Alqarni A; Jasim SA; Altalbawy FMA; Kaur H; Kaur I; Rodriguez-Benites C; Deorari M; Alwaily ER; Al-Ani AM; Redhee AH
J Biochem Mol Toxicol; 2024 Jun; 38(6):e23719. PubMed ID: 38764138
[TBL] [Abstract][Full Text] [Related]
3. Tackling Resistance to Cancer Immunotherapy: What Do We Know?
Gondhowiardjo SA; Handoko ; Jayalie VF; Apriantoni R; Barata AR; Senoaji F; Utami IJW; Maubere F; Nuryadi E; Giselvania A
Molecules; 2020 Sep; 25(18):. PubMed ID: 32911646
[TBL] [Abstract][Full Text] [Related]
4. Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus.
Meng Q; He J; Zhong L; Zhao Y
Int J Med Sci; 2021; 18(11):2294-2302. PubMed ID: 33967605
[TBL] [Abstract][Full Text] [Related]
5. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
6. [Immunotherapy Against Head and Neck Cancer Stem Cells].
Coordes A; Ochsenreither S; Qian X; Hofmann VM; Meyer JE; Karl Hoffmann T; Kaufmann AM; Albers AE
Laryngorhinootologie; 2017 Apr; 96(4):216-224. PubMed ID: 28493252
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy: A Potential Approach to Targeting Cancer Stem Cells.
Wang W; Bai L; Xu D; Li W; Cui J
Curr Cancer Drug Targets; 2021; 21(2):117-131. PubMed ID: 32364076
[TBL] [Abstract][Full Text] [Related]
8. Combined strategies for tumor immunotherapy with nanoparticles.
Savitsky K; Yu X
Clin Transl Oncol; 2019 Nov; 21(11):1441-1449. PubMed ID: 31055713
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
Amedei A; Niccolai E; Prisco D
Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
[TBL] [Abstract][Full Text] [Related]
11. Immunologic Targeting of Cancer Stem Cells.
Zhang J; Li Q; Chang AE
Surg Oncol Clin N Am; 2019 Jul; 28(3):431-445. PubMed ID: 31079798
[TBL] [Abstract][Full Text] [Related]
12. Tumor Plasticity and Resistance to Immunotherapy.
Horn LA; Fousek K; Palena C
Trends Cancer; 2020 May; 6(5):432-441. PubMed ID: 32348738
[TBL] [Abstract][Full Text] [Related]
13. Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches.
Pan Q; Li Q; Liu S; Ning N; Zhang X; Xu Y; Chang AE; Wicha MS
Stem Cells; 2015 Jul; 33(7):2085-92. PubMed ID: 25873269
[TBL] [Abstract][Full Text] [Related]
14. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
Kim N; Kim HS
Front Immunol; 2018; 9():2041. PubMed ID: 30250471
[TBL] [Abstract][Full Text] [Related]
15. Engineered dendritic cells for gastrointestinal tumor immunotherapy: opportunities in translational research.
Bhargava A; Mishra D; Banerjee S; Mishra PK
J Drug Target; 2013 Feb; 21(2):126-36. PubMed ID: 23061479
[TBL] [Abstract][Full Text] [Related]
16. Identification of inhibitory immune checkpoints and relevant regulatory pathways in breast cancer stem cells.
Shi H; Yang Y
Cancer Med; 2021 Jun; 10(11):3794-3807. PubMed ID: 33932112
[TBL] [Abstract][Full Text] [Related]
17. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
Front Immunol; 2018; 9():2905. PubMed ID: 30619269
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cell-based immunotherapy: From transplantation toward targeting cancer stem cells.
Dianat-Moghadam H; Rokni M; Marofi F; Panahi Y; Yousefi M
J Cell Physiol; 2018 Jan; 234(1):259-273. PubMed ID: 30144312
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Xue T; Budde LE
Hematol Oncol Clin North Am; 2020 Jun; 34(3):575-587. PubMed ID: 32336421
[TBL] [Abstract][Full Text] [Related]
20. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
